In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-β-D-dioxolane- guanosine and suppress resistance to 3'-azido-3'-deoxythymidine

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 7, 2000, Pages 1783-1788

  Bazmi, Holly Z ^a   Hammond, Jennifer L ^a   Cavalcanti, Socrates C H ^b   Chu, Chung K ^b   Schinazi, Raymond F ^c   Mellors, John W ^a,d,e,f  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; 2 AMINO 6 CHLOROPURINE DIOXOLANE; ADEFOVIR; ANTIRETROVIRUS AGENT; BETA DEXTRO 2,6 DIAMINOPURINE DIOXOLANE; BETA DEXTRO DIOXOLANE GUANOSINE; BETA DEXTRO DIOXYLANYL 5 FLUOROCYTOSINE; DIDANOSINE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG STRUCTURE; GENE SEQUENCE; GENETIC SELECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; STRAIN DIFFERENCE; VIRUS ISOLATION; VIRUS MUTATION;

CELLS, CULTURED; COMPUTER SIMULATION; DIOXOLANES; DRUG RESISTANCE, MICROBIAL; GUANOSINE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 0033921632     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.7.1783-1788.2000     Document Type: Article

References (30)

1. Arion, D., N. Kaushik, S. McCormick, G. Borkow, and M. A. Parniak. 1998. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37: 15908-15917.
2. Balzarini, J., A. Karlsson, M. J. Perez-Perez, M. J. Camarasa, W. G. Tarpley, and E. De Clercq. 1993. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J. Virol. 67:5353-5359.
3. Buckheit, R, W., T. L. Kinjerski, V. Fliakas-Boltz, J. D. Russell, T. L. Stup, L. A. Pallansch, W. G. Brouwer, D. C. Dao, W. A. Harrison, R. J. Schultz, J. P. Bader, and S. S. Yang. 1995. Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type 1-specific compounds related to oxathiin carboxanilide. Antimicrob. Agents Chemother. 39:2718-2727.
4. Chen, H., F., D. Boudinot, C. K. Chu, H. M. McClure, and R. F. Schinazi. 1996. Pharrnacokinetics of (-)-β-D-2-aminopurine dioxolane and (-)-β-D-2-amino-6-chloropurine dioxolane, and their antiviral metabolite (-)-β-D-dioxolane guanine in rhesus monkeys. Antimicrob. Agents Chemother. 40: 2332-2336.
5. Condra, J. H., W. A. Schleif, O. M. Blany, L. Gabryelski, D. Graham, J. Quintero, A. Rhodes, H. Rabbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. Squires, P. Deutsch, and E. Emini. 1995. In vivo emergence of HIV-1 to variants resistant to multiple protease inhibitors. Nature 374:569-571.
6. De Clercq, E. 1994. HIV resistance to reverse transcriptase inhibitors. Biochem. Pharmacol. 47:155-169.
7. Gu, Z., Q. Gao, H. Fang, H. Salomon, M. A. Parniak, E. Goldberg, J. Cameron, and M. A. Wainberg. 1994. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 38:275-281.
8. Gu, Z., M. A. Wainberg, N. Nguyen-BA, L. L'Heureux, J.-M. de Muys, T. L. Bowlin, and R. F. Rando. 1999. Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob. Agents Chemother. 43:2376-2382.
9. Huang, H., R. Chopra, G. L. Verdine, and S. C. Harrison. 1998. Structure of a covalently trapped catalytic complex of HIV-1reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
10. Kirn, H. O, R. F. Schinazi, K. Shanmuganathan, D. L. Cannon, A. J. Alves, L. S. Jeong, J. W. Beach, and C. K. Chu. 1993. 1,3-Dioxolanylpurine nucleosides (2R, 4R) and (2R, 4S) with selective anti-HIV-1 activity in human lymphocytes. J. Med. Chem. 36:30-37.
11. Kinjerski, T. L., and R. W. Buckheit, Jr. 1997. The role of genotypic heter-ogeneity in wild type virus populations on the selection of non-nucleoside reverse transcriptase inhibitor resistant viruses. Antivir. Res. 33:109-115.
12. Kleim, J. P., I. Winkler, M. Rosner, R. Kirsch, H. Rubsamen-Waigmann, A. Paessens, and G. Riess. 1997. In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097. Virology 231:112-118.
13. Larder, B. A. 1992. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36:2664-2669.
14. Larder, B. A. 1995. Viral resistance and the selection of antitetroviral combinations. J. Acquired Immune Defic. Syndr. 10:S28-S33.
15. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
16. Martin, J. L., J. E. Wilson, R. L. Haynes, and P. A. Furman. 1993. Mechanism of resistance of human immunodeficiency virus type 1 to 2′,3′-dideoxyinosine. Proc. Natl. Acad. Sci. USA 90:6135-6139.
17. Mellors, J. W, G. J. Im, E. Tramontano, S. R. Winkler, D. J. Medina, G. E. Dulschman, H. Z. Bazmi, G. Piras, C. J. Gonzalez, and Y. C. Cheng. 1992. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(55)-4,5,6.7-retrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5,1 -jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150). Mol. Pharmacol. 43:11-16.
18. Mellors, J. W., G. E. Dutschman. B. J. Im, E. Tramontano, S. R. Winkler, and Y.-C. Cheng. 1992. In vitro selection and molecular characterization of human immunodeficiency virus type 1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol. Pharmacol. 41:446-451.
19. Mellors, J. W., H. Z. Bazmi, R. F. Schinazi, B. M. Roy, Y. Hsiou, E. Arnold, J. Wir, and D. L. Mayers. 1995. Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob. Agents Chemother. 39:1087-1092.
20. Meyer, P. R., S. E. Matsuura, A. G. So, and W. A. Scott. 1998. Unblocking of chain-terminated primer by HlV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl. Acad. Sci. USA 95:13471-13476.
21. Nguyen, M. H., R. S. Schinazi, C. Shi, N. M. Goudgaon, P. M. NcKenna. and J. W. Mellors. 1994. Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl and 6-phenylthiopyrimidines. Antimicrob. Agents Chemother. 38:2409-2414.
22. Rajagopalan, P., F. D. Boudinot, C. K. Chu, B. C. Tennant, B. H. Baldwin, and R. F. Schinazi. 1996. Pharmacokinetics of (-)-β-D-2,6-diaminopurine dioxolanc and its metabolite, dioxolane guanosine, in woodchucks (Mamiota monax). Antivir. Chem. Chemother. 7:65-70.
23. Reed, L. J., and H. Muench. 1938. A simple method for estimating fifty percent end points. Am. J. Hyg. 27:493-496.
24. Richman, D. D. 1993. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother. 37: 1207-1213.
25. Schinazi, R. F, J.-P. Sommadossi, V. Saalmann, D. L. Cannon, M.-Y. Xie, G. Hart, G. C. Smith, and E. F. Hahn. 1990. Activity of 3′-azido-3′-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 34:1061-1067.
26. Schinazi, R. F., H. M. McClure, F. D. Boudinot, Y. Xiang, and C. K. Chu. 1994. Development of (-)-(β-D-2,6-diaminopurine dioxolane as a potential antiviral agent. Antivir. Res. 23:81.
27. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 1997. Mutations in retroviral genes associated with drug resistance. Int. Antivir. News 5(8):129-142.
28. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to DDI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
29. Tachedjian, G., J. Mellors, H. Bazmi, C. Birch, and J. Mills. 1996. Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. J. Virol. 70:7171-7181.
30. Zhang, D., A. M. Caliendo, J. J. Eron, E. M. DeVore, J. C. Kaplan, M. S. Hirsch, and R. T. D'Aquila. 1994. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38:282-287.